Recipharm, Astimex form development and manufacturing collaboration

Friday, October 12, 2012 11:58 AM

Recipharm, a Swedish contract development and manufacturing organization, and Astimex Pharma, a Swedish pharmaceutical company, have formed a collaboration agreement for the development and manufacture of a pharmaceutical product.

The formulation development work will take place at the Recipharm Pharmaceutical Development site located in Solna, close to Stockholm. Astimex Pharma also has the opportunity to choose Recipharm as the future manufacturer for the product.

Additionally, Astimex is in discussions with Recipharm for engagement to carry out other manufacturing and development contractual projects. 

“I am convinced that this is the start of a long-term collaboration that will prove beneficial for both companies and we are pleased that Astimex Pharma has chosen to utilize the expertise and flexible development capabilities that our staff and facilities are able to provide,” said Maria Lundberg, general manager, Recipharm Pharmaceutical Development.

“It is Recipharm’s recognized partnering approach, combined with its advanced and adaptable capabilities, including its offering at the Solna facility, that attracted us in the first place,” said Åsa Lintzen, general manager, Astimex Pharma. “Moreover, we were looking for a CDMO that we could build a long term relationship with and consequently we are already exploring the scope for working with Recipharm on other projects.”     

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs